Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.

Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

An abstract is available from the original source but is not redistributed by this database. Read the source record.

Open source BibTeX RIS

Read this study in context

This report is included in a selected evidence comparison. Review its population, primary endpoint, findings and limitations alongside the other selected reports.

These original educational annotations are not an exhaustive systematic review or a clinical guideline.

Bibliographic context

Journal
Journal of psychopharmacology (Oxford, England)
Date
2016-12-01
Source
PubMed
DOI
10.1177/0269881116675513
PubMed
27909165
Record provenance and attribution

The listed authors receive credit for the original research. This tracker aggregates source metadata and derives discovery labels; inclusion is not scientific validation.

Source identifier
Indexed
2026-07-01 06:54:14 UTC
Metadata last checked
2026-08-09 08:28:27 UTC

Checking metadata does not mean individual manual review. Cite the original work for its findings and the exact dataset snapshot and software version for analyses.

Machine-readable provenance

Authors

Watch author

Derived topics and classifications

These labels are search aids derived from indexed metadata, not an assessment of evidence quality. Verify the study design and findings in the original source.

Citation graph

0 referenced DOIs found in stored source metadata. 20 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurement2026-12-01Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery model2026-12-01Changes in self-related cognitive processes and depressive symptom severity following a single, moderate dose of psilocybin in depressed patients2026-11-10Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis2026-11-01Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression2026-11-01The 'Civilising' of Psychedelics: Pharmaceuticalisation from Below as a Part-Process of American and European Informalisation2026-10-30Clinical Evidence on Psilocybin and Its Representation in Media Reporting2026-10-20Psychedelics in neurosurgery: Potential utility in prevention, perioperative care, pain management, and neurorehabilitation2026-10-09Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis2026-10-08Study participant perceptions of the relevance of therapist and study team personal psychedelic experience2026-10-03A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults2026-09-21Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD2026-09-08Through the Looking-Glass: A Scoping Review of Psychological Mechanisms of Psychedelic-Assisted Therapy for Substance Use Disorders2026-09-02PSYCHEDELICS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER AND DEPRESSION: A REVIEW OF CLINICAL TRIALS2026-08-31Ayahuasca and Salvia divinorum as contrasting modes of consciousness reorganization: Implications for psychedelic-assisted psychotherapy2026-08-13Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic framework2026-08-12Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)2026-08-12The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis2026-08-01Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial2026-07-30Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping review2026-07-26

Related papers

No close related records were found yet.